XORTX presented on the American Society of Nephrology – Kidney Week 2024 and

Gesundheitliche following an active

CALGARY, ALBERTA, August 20, 2024 / IRW-Press / XORTX Therapeutics Inc. (“XORTX” or “Unternehmen”) (NASDAQ: XRTX | TSXV: XRTX | FWB: ANU), An Pharmaceutical drugs in the späten clinical phase, when it comes to innovative therapies for the treatment of non-recoverable diseases, it may happen that it is a at the American Society of Nephrology (“ASN”). The Abstract with the Title “Xanthine oxidase in rats, mice and humans with polycystic kidney disease” (Xanthin oxidase in rats, mice and humans with polycystic kidney disease) was assessed by ASN-Prüfungsausschuss for the scientific merits and new research. The University of Colorado study at Dr. Charles Edelstein was performed and sponsored by XORTX. This is the session with the title “Genetic diseases: cystic – therapeutic research and prognosis” (Genetic Diseases: Zystische Erkrankungen – Therapeutische Untersuchungen und Prognosen) präsentiert.

About this study

The enzyme Xanthinoxidase (‘XO’) is an essential enzyme, which contains the resins of the substance, and which is useful for the abbreviation of purine nucleotides. The resin is a reactive type of sauerstoff, which is released by the enzymatic reaction, whereby the disease-killing can become a damaging role in the circular running system and in web games. The new track-breaking discoveries in animal models of polycystic kidney disease (“PKD”) have created an overexpression or overactivity of XO. It is not possible to use an overexpression or overactivity of XO in people with PKD or a progressive progression of the associated disease. Soul of the Study Wars, Recognition of your gains, with a high XO-Activity for a Zystenwachstum führt. The XO-activities work at PCK(i)-Rats, PKD1RC/RC (RC)-Mäusen and 34 patients from the clinical HALT-PKD-Study collected.

In my summary the study studies were done using the mouse, rat and human studies of PKD. If you do research you can see more about the xanthin oxidase active substance (XOa) in the serum in the different PKD levels and that active action with the volume and the amount of glomerular filtration rate (GFR) in the setszen. The research has had a great influence on the abnormal clearance in the PKD web on the XO enzyme activation with the concentration of zirconium resins, the enlargement of the kidneys and the enzymes that can improve its functional action of the glomerular filtration rate. Previous study results cannot say that an overexpression of XO in the PKD kidney network is a Remarkably a enzyme that can be used. XORTX will be a new update of the results of the previous study in the first week of November.

Dr. Allen Davidoff, CEO of XORTX, said, “There will be a poster presentation at the American Society of Nephrology Annual Meeting during Kidney Week 2024, a new study on the PKD study. The bottom line is that the research on data material from mouse and rat models of human studies of PKD is of negligible merit, which can show a high level of serum resin concentration or an abnormal expression of XO in the renal web with a rapid damage. The XRx-008 program is looking forward to a new knowledge, which uses the Xanthinoxidase Value bzw. an active Xanthinoxidase is followed by a PKD that can be displayed. “

View the American Society of Nephrology’s Kidney Week

The ASN cares for more than 21,000 kidney patients who care for people with kidney disease and their families. (Source: https://www.asn-online.org/)

The Kidney Week Conference 2024 in Orlando, Florida, with 10,000 kidney specialists from all parts of the world considered. The Kidney Week is the most important meeting of nephrology and offers the opportunity to awaken the disease and to respond to the wisdom sauce, the knowledge of new research and medical fortifications will be an exciting and provocative discussion with leading experts in the area. (Source: https://www.asn-online.org/education/nierweek/ American Society of Nephrology – Program and Abstracts)

The Kidney Week program has started ASN website available. The abstracts will be available on the ASN website on October 14, 2024.

About ADPKD

ADPKD is a rare disease that has affected more than 10 million people since. 1,2 ADPKD is usually performed with the correct diagnosis of automatic diagnosis. I can spend time expanding and expanding the structure and functionality of the change of new features and developing chronic symptoms, which for ADPKD patients3 typically a serious problem.

Once you have found the source of the healthy substance, which functions as a combination of the Zysten technology, then it is another pleasure of the kidney function, a fibrosis, which has a good effect on the kidneys and another kidney function ließlich zu een Renal disease in the Endstadium führt.1 There are reports that the following messages are a high level of concern in the ADPKD patient, one of the most important warnings of Nierensteinen5 and Gicht.6.7 For people with progressive ADPKD it is important that there is a blood pressure-sensitive treatment that contains a number of errors. For a treatment of patients who want to perform a pharmaceutical therapy4It is new that more and more therapies are being used, one of the patients who work with ADPKD treatment.

Sources:

1. Wiley C., Kamat S., Stelhorn R., Blais J., Analysis of national data to determine the incidence and diagnosis of autosomal dominant polycystic kidney disease in the US, Kidney Disease, 5(2): 107-117, 2019
2. Bergmann C., Guay-Woodford LM, Harris PC, Horie S., Peters DJ, Torres VE, Polycystic kidney disease, Nat Rev Dis Primers. 4(1): 50, 2018
3. https://pkdcure.org/living-with-pkd/chronic-pain-management
4. Gimpel C., Bergmann C., Bockenhauer D., et al., International consensus statement on the diagnosis and treatment of autosomal dominant polycystic kidney disease in children and adolescents, Nat Rev Nephrol 15(11):713-726, 2019
5. Torres VE, et al, The association of nephrolithiasis and autosomal dominant polycystic kidney disease, Am J Kidney Dis, 1988, vol 11, 318-325
6. Newcombe, DS. Brief Gouty arthritis and polycystic kidney disease, Ann Intern Med, 1973 vol 79, pg 605
7. Rivera JV Martinez, et al, Association of hyperuricemia and polycystic kidney disease, Bol Asoc Med PR, 1965 vol 7 251-263

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company that has developed the products in the clinical stage of the stadium: 1) a XRx-008 main program for the treatment of ADPKD and 2) a side program with XRx-101 for the treatment of the kidney damage, so that others also an organ in Zusammenhang with the mCoronavirus / COVID-19 infection. Use an XRx-225, a program in the foreclinical stadium for the treatment of a nephropathy in type 2 diabetes, equipment.

XORTX works in the clinical lung stage of clinical development of products, which work on a metabolic and xanthinoxidase basis and distort the resin production or so much so. With XORTX you have a drug treatment, the quality of health care and the care of patients that serve you. Check out the information about XORTX below www.xortx.com.

For further information please contact:

Allen Davidoff, CEO

[email protected]

+1 403 455 7727

Nick Rigopulos, Director of Communications

[email protected]

+1 617 901 0785

Kim Golodetz, LHA Investor Relations

[email protected]

+1 212 838 3777

Neither the TSX Venture Exchange nor the Nasdaq conducted the press conference or the missbilligt. No stock exchange, paperwork commission or other supervisory authority generated or authorized the information contained herein.

Future-oriented excursions

These press conferences will be postponed or will be postponed due to current Federal Government Papers. You can view the following things, such as the following: Pläne, Ziele, Zielsetzungen, Erwartungen, Annahmen, Schätzungen, Absichten, zukünftigen Leistungen des Unternehmens, other Aussagen, die not set any historical facts, so wie Aussagen, die by Wörter wie ‘erwartet “, “antizipiert”, “beabsichtigt”, “plant”, “glaubt”, “strebt an”, “schätzt” or Wörter mit ähnlicher Bedeutung gekennzeichnet sind. These targeted measures and the resulting consequences are based on the management of XORTX management and the execution of a factory traveler and an uncontrolled approach, so that the tatsächlichen are very good at the task in question schriebenen abweichen. If the risks, the debts and other factors may occur, among other things, the financial resources used, the constriction in the future in the future, the capital and the capital, the time and the timeless plans exclude and clinical studies, the Leistung von Drittherstellern and Research Institutes, our companies for the sales and sale of product candidates, our companies, which offer on the market other other new markets, and our good quality, the market of the spirited Properties for our product candidates are erhalten and aufrechtzuerhalten. If you have no rights or other written documents, XORTX not clarified, but it is not possible to view an example or a standard on the date of the documents or the original version. More useful information about the risks and exposures that XORTX entails is included in the “Risk Factors” in XORTX’s Annual Report on Form 20-F, which is filed with the SEC and is available on the SEC’s website www.sec.gov it is paintless (one piece of documentation, which is a part of the document that has been published since then), anyway in our reports, open documents and other documents and other documents and other documents in Canada, which are unter www.sedarplus.ca inflating phrase.

The Ausgangssprache (in the Rule English), in the original text which is light, is the official, authorizing and legally binding version. These instructions can be carried out with confidence. The German language can be kürzt or jijammengefasst. There is no Verantwortung or Haftung für de Inhalt, de Direction, de Angemessenheit or de Genauigkeit dieser Übersetzung übernommen. Aus Sicht des Übersetzers stelltt die Notification keine Kauf- oder Verkaufsempfehlung dar! Bitte beachten Sie that English original report www.sedarplus.ca, www.sec.gov or on the company website!